Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 16.59B P/E 238.89 EPS this Y 83.90% Ern Qtrly Grth -
Income 167.64M Forward P/E 35.22 EPS next Y 69.40% 50D Avg Chg -1.00%
Sales 2.42B PEG 1.32 EPS past 5Y -6.40% 200D Avg Chg -8.00%
Dividend N/A Price/Book 3.48 EPS next 5Y 43.00% 52W High Chg -25.00%
Recommedations 2.00 Quick Ratio 1.45 Shares Outstanding 189.78M 52W Low Chg 10.00%
Insider Own 0.84% ROA 1.63% Shares Float 187.23M Beta 0.32
Inst Own 100.76% ROE 3.51% Shares Shorted/Prior 3.06M/3.06M Price 88.39
Gross Margin 47.85% Profit Margin 6.93% Avg. Volume 1,238,693 Target Price 109.70
Oper. Margin 4.37% Earnings Date Apr 24 Volume 1,105,230 Change -0.69%
About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc. News
09:01 AM BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
04/12/24 Insider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
04/10/24 BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
04/01/24 Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
03/28/24 Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
03/16/24 4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
03/12/24 New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
03/11/24 BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
03/08/24 Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...
03/07/24 BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
03/01/24 BioMarin Scheduled to Participate in March Investor Conferences
02/27/24 Decoding Biomarin Pharmaceutical Inc (BMRN): A Strategic SWOT Insight
02/26/24 REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies
02/24/24 BioMarin Pharmaceutical Full Year 2023 Earnings: EPS: US$0.89 (vs US$0.76 in FY 2022)
02/23/24 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2023 Earnings Call Transcript
02/23/24 BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
02/23/24 Q4 2023 Biomarin Pharmaceutical Inc Earnings Call
02/23/24 20 Fastest Growing Biotech Companies in the US
02/23/24 BioMarin preaches patience amid slow sales for hemophilia gene therapy
02/22/24 Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings
BMRN Chatroom

User Image mauriz Posted - 1 day ago

$BMRN $96.00 Is my short time target

User Image mauriz Posted - 1 day ago

$BMRN hello ! new on biomarin . In for a swing trade in sight of QR

User Image scienceleads Posted - 1 day ago

$BMRN poised for growth with 2 recently approved drugs.

User Image muldoon92 Posted - 1 day ago

@Here4theartcle 💯 they’ve been talking about $BMRN as a prime takeover target for almost a decade now. Seems about right time to wrap it up with a bow tie and send it on its way

User Image swingcobra Posted - 1 day ago

@sogenerous true. $BMRN seemed to have bounced off its recent lows.

User Image muldoon92 Posted - 3 days ago

$BMRN something is clearly going on here… I’ve been largely ignoring my position for last few years bc of how boring it’s been. But this is… different. If I see followthrough Monday will add size. Something seems amidst this week

User Image Tradelearner2022 Posted - 3 days ago

$BMRN - Strong uptrend heading towards earnings.

User Image muldoon92 Posted - 5 days ago

$BMRN this has no reason at all to be positive today… something brewing? Activist team working on a buyout?

User Image insiderbuyingselling Posted - 5 days ago

$BMRN new insider selling: 2286 shares. http://insiderbuyingselling.com/?t=BMRN

User Image CDMO Posted - 5 days ago

$BMRN again very strong

User Image Top_Dog_Pro_Trader Posted - 1 week ago

$BMRN type of accumulation on a down day that makes you think its getting aquired!

User Image TheClockworkGroup Posted - 1 week ago

$BMRN #NASDAQ | The markets are unpredictable, but with hashtag#WaveE, one of our cutting-edge hashtag#AI-driven hashtag#algorithmic hashtag#breakout hashtag#daytrading strategies, you can make calculated trades like a pro! Scalped profits of $2,599.15 trading hashtag#BiomarinPharmaceutical, $BMRN shares today! Experience 100% automation! Experience 100% automation and compatibility with @MultiCharts, @NinjaTrader & @TradeStation...

User Image trendtrader6 Posted - 1 week ago

$BMRN daily chart breaking out of a short term set up. looks like it should test the medium term setup at 94ish soon.

User Image trendtrader6 Posted - 1 week ago

$BMRN weekly chart. great strength today in a choppy marker. 95/100/110

User Image BasedInvestor Posted - 1 week ago

$BMRN seeing a lot of unusual calls on the Bullflow unusual options platform, anyone know of upcoming catalysts for this stock?

User Image CDMO Posted - 1 week ago

$BMRN 90 on a day like this 🤔🤔

User Image scienceleads Posted - 1 week ago

$BMRN always a bull market somewhere as the sayings goes

User Image Stock_Titan Posted - 1 week ago

$BMRN BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET https://www.stocktitan.net/news/BMRN/bio-marin-to-host-first-quarter-2024-financial-results-conference-tddca4e9jz7t.html

User Image ca_rott1487 Posted - 1 week ago

$BMRN Even if the deadline has passed you can still file for a late claim.

User Image B9YCE Posted - 03/26/24

$BMRN super long

User Image swingcobra Posted - 03/25/24

$BMRN seems to be turning around with no news. Maybe selling is slowing down. Volume slightly lower. Need buyers to sustain rally.

User Image l4ndsh4rk Posted - 03/25/24

$BMRN Setting up, needs a catalyst

User Image scienceleads Posted - 03/19/24

$BMRN there’s a lot of moving parts here and their gene therapy intellectual property is a key attraction-they own all of it. IMO it’s a big plus going forward.

User Image MurderWasp Posted - 03/18/24

$BMRN Top of the heap

User Image jsims07 Posted - 03/18/24

User Image StockBraker Posted - 1 month ago

$BMRN New data to be presented for BioMarin''s VOXZOGO (vosoritide) in Children with Hypochondroplasia and Achondroplasia SAN RAFAEL, Calif. , March 12, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate VOXZOGO''s positive impact on quality of life.

User Image Stock_Titan Posted - 1 month ago

$BMRN New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting https://www.stocktitan.net/news/BMRN/new-data-to-be-presented-for-bio-marin-s-voxzogo-r-vosoritide-in-w34bpic6lih9.html

User Image InsiderPeek Posted - 1 month ago

$BMRN Chief Commercial Officer Ajer Jeffrey Robert sold 4k shares for $348.3k (ownership down 4.08%) insiderpeek.com/company/BMRN

User Image G101SPM Posted - 1 month ago

#OPTIONACTION $MSTR Mar 1400 calls are seeing interest with the underlying stock up 4% (volume: 2940, open int: 960, implied vol: ~247%, prev day implied vol: 161%). Bitcoin reached $70,000. Co is expected to report earnings late April. $FSLR Mar 165 calls (volume: 2500, open int: 950, implied vol: ~75%, prev day implied vol: 57%). Co is expected to report earnings late April. $FIVN Mar 65 puts (volume: 1700, open int: 0, implied vol: ~82%, prev day implied vol: 46%). 1190 contracts traded in a single transaction. Co is expected to report earnings late April. $BMRN Apr 80 puts (volume: 4660, open int: 0, implied vol: ~29%, prev day implied vol: 28%). Nearly all the volume occurred in a single transaction. Co is expected to report earnings late April.

User Image Top_Dog_Pro_Trader Posted - 1 month ago

$BMRN seems like a setup for a Roche BO IMO. They showed interest before. Hopefully can get Rox rolling…would be the lighter fluid needed for this to take off!

Analyst Ratings
Canaccord Genuity Hold Feb 29, 24
Piper Sandler Overweight Feb 23, 24
Cantor Fitzgerald Overweight Feb 23, 24
RBC Capital Sector Perform Feb 23, 24
Baird Outperform Jan 30, 24
Stifel Buy Dec 21, 23
RBC Capital Sector Perform Nov 7, 23
BMO Capital Outperform Nov 3, 23
Piper Sandler Overweight Nov 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BIENAIME JEAN JACQUES Director Director Jan 08 Sell 97.29 20,000 1,945,800 425,162 01/11/24
BIENAIME JEAN JACQUES Director Director Jan 08 Option 63.1 20,000 1,262,000 435,162 01/11/24
BIENAIME JEAN JACQUES Director Director Dec 21 Sell 93.99 10,000 939,900 425,112 12/22/23
BIENAIME JEAN JACQUES Director Director Dec 21 Option 63.1 10,000 631,000 435,112 12/22/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Dec 13 Sell 95.30 13,764 1,311,709 55,710 12/14/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 16 Sell 90 5,000 450,000 60,804 08/17/23
FUCHS HENRY J President, Worldwide.. President, Worldwide R&D Aug 10 Sell 90.4259 12,000 1,085,111 176,187 08/11/23
Guyer Charles Greg EVP, Chief Technical.. EVP, Chief Technical Officer Aug 09 Sell 93.304 5,360 500,109 40,041 08/10/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 08 Sell 89.4238 11,000 983,662 69,474 08/09/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Aug 07 Sell 88.2 10,000 882,000 422,732 08/09/23
MEIER RICHARD A Director Director May 12 Option 67.81 8,500 576,385 117,494 05/17/23
HERON ELAINE J Director Director May 12 Option 67.81 8,500 576,385 94,068 05/17/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 12 Option 67.81 46,500 3,153,165 472,713 05/16/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 11 Sell 94.89 30,000 2,846,700 426,213 05/15/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer May 11 Option 67.81 30,000 2,034,300 456,213 05/15/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 28 Sell 95.12 60,000 5,707,200 426,213 05/11/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 28 Option 67.81 60,000 4,068,600 456,213 05/11/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 06 Sell 96.13 10,000 961,300 425,896 04/10/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 06 Option 67.81 10,000 678,100 435,896 04/10/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Mar 10 Sell 91.37 23,000 2,101,510 487,856 03/14/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Mar 10 Option 67.81 23,000 1,559,630 495,856 03/14/23
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Feb 24 Option 67.81 1,474 99,952 56,725 02/28/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Jan 25 Sell 115.9 49,000 5,679,100 41,088 01/27/23
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Jan 25 Option 67.81 49,000 3,322,690 90,088 01/27/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Jan 13 Option 67.81 20,000 1,356,200 330,424 01/18/23
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Jan 13 Sell 111.9 20,000 2,238,000 320,424 01/18/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jan 13 Sell 114.5 2,500 286,250 27,746 01/17/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jan 13 Option 63.1 2,500 157,750 30,246 01/17/23
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 13 Option 63.1 2,500 157,750 30,246 12/15/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 13 Sell 107.5 2,500 268,750 27,746 12/15/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 02 Option 67.81 5,900 400,079 31,507 12/06/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Dec 02 Sell 104.5 7,001 731,604 27,746 12/06/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Nov 02 Sell 104 1,500 156,000 321,424 12/06/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Nov 23 Option 67.81 3,500 237,335 32,347 11/28/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Nov 23 Sell 98.03 5,379 527,303 28,847 11/28/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Oct 31 Sell 86.55 1,500 129,825 322,824 11/01/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 89.89 4,000 359,560 324,324 10/18/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Aug 12 Sell 94.98 7,000 664,860 328,324 08/16/22
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Aug 11 Sell 95.62 3,000 286,860 44,088 08/12/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 09 Option 67.81 47,526 3,222,738 102,777 08/11/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Aug 09 Sell 96.14 51,216 4,923,906 55,251 08/11/22
Guyer Charles Greg EVP, Chief Technical.. EVP, Chief Technical Officer Aug 08 Sell 96.56 6,205 599,155 42,168 08/10/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Aug 05 Option 67.81 3,500 237,335 34,226 08/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Aug 05 Sell 94.5 3,500 330,750 30,726 08/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Jul 08 Sell 89.50 7,337 656,662 30,726 07/12/22
Davis George Eric EVP, Chief Legal Off.. EVP, Chief Legal Officer Jul 08 Sell 90.00 7,398 665,820 58,941 07/11/22
Ajer Jeffrey Robert EVP, Chief Commercia.. EVP, Chief Commercial Officer Apr 29 Sell 78.94 1,308 103,254 54,109 05/31/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 29 Option 37.46 30,000 1,123,800 355,324 05/09/22
BIENAIME JEAN JACQUES Chief Executive Offi.. Chief Executive Officer Apr 29 Sell 82.57 30,000 2,477,100 335,324 05/09/22
Mueller Brian EVP, Chief Financial.. EVP, Chief Financial Officer Apr 29 Option 37.46 11,800 442,028 48,401 05/06/22